Clint Valentine, MS from TwinStrand Biosciences discusses TwinStrand Biosciences Announces Peer-Reviewed Publication of Study Results Highlighting Ability of Duplex Sequencing Technology to Rapidly Detect the Mutagenic Activity of Chemicals.
SEATTLE, Feb. 25, 2020 /PRNewswire/ — At the annual General Meeting of Advances in Genome Biology and Technology (AGBT) in Marco Island, Florida, TwinStrand BiosciencesTM, a next-generation DNA sequencing technology company, today announced the launch of TwinStrand Duplex SequencingTM Technology kits. At its launch, the company will offer its technology platform for two research applications: the identification of minimal residual diseases in patients with acute myeloid leukemia (AML MRD) and the multi-species genetic toxicology assay to rapidly recognize carcinogenic chemicals in preclinical trials, as well as the detection of patients that have been exposed to the setting.
Duplex SequencingTM is an upgrade focused on biochemistry and software to existing next-generation sequencing platforms that enhances precision by more than 10,000-fold. This drastic improvement in output helps researchers and clinicians to solve previously intractable genetic “needle in a haystack” problems by exposing the faint signals of DNA mutations of ultra-low frequency that have been hidden by technological noise until now.
TwinStrand Duplex Sequencing Technology works on a simple two-step process that makes it easy for any customer without the need for special resources or equipment to conduct the complete DNA-to-data workflow. The platform capitalizes on optimized chemistry, which allows the user to complete the preparation of the library in 1-2 days, and cloud-based computer software, which allows multi-terabyte raw sequencing data to be completely processed, analyzed, interpreted, and graphically displayed in an easy but efficient way, without the need for dedicated programmers or local high-powered computer hardware.
Organizations that have been unable to apply the power of next-generation DNA sequencing to a field dominated by older technologies now have a cutting-edge, highly sensitive, and scalable product with TwinStrand’s genetic toxicology application that allows for early detection of carcinogenic chemicals years earlier than traditional methods. The AML MRD offering from TwinStrand has demonstrated residual disease detection at levels that are orders of magnitude lower than the nearest competitive sequencing technology, allowing for much more accurate stratification of patient risk.